Syndax Pharmaceuticals Inc (SNDX)

Over the past six months, Syndax Pharmaceuticals' stock price has increased by approximately 124.97%. Key events impacting the stock include FDA approvals for Revuforj, earnings reports indicating revenue performance, analyst ratings with a consensus of "Strong Buy", and presentation at the J.P. Morgan Healthcare Conference.

Information regarding specific demand seasonality for Syndax Pharmaceuticals, Inc. products and services is not explicitly available. The demand for its products is likely driven by ongoing patient needs and disease prevalence rather than typical seasonal fluctuations. The company's focus on unmet medical needs suggests a more consistent demand profile, influenced by clinical trial outcomes, regulatory approvals, and physician adoption, rather than seasonal patterns.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that has transitioned into a commercial-stage oncology company. The company is dedicated to developing innovative therapies for cancer and other serious diseases, focusing on areas of significant unmet medical need such as acute leukemia and chronic graft-versus-host disease (cGVHD). Its major products include Revuforj (revumenib), a selective menin-MLL inhibitor approved for KMT2A-rearranged and NPM1-mutant acute leukemias; Niktimvo (axatilimab), a monoclonal antibody approved for chronic graft-versus-host disease (cGVHD); and Entinostat, an oral HDAC inhibitor in late-stage clinical trials.

Syndax Pharmaceuticals' business activity is primarily centered in the United States. The company is also actively working to expand the global reach of its therapies through a multi-regional managed access program to expand access to Revuforj (revumenib) outside the U.S.

Syndax Pharmaceuticals has significantly enhanced its brand reputation over the past year, primarily driven by its successful transition to a commercial-stage oncology company and the positive reception of its key products. Revuforj was recognized as the "Best New Drug at the Scrip Awards 2025", and the company secured three FDA approvals within approximately 14 months. Both Revuforj and Niktimvo have shown strong demand and revenue growth since their launches.

Approximately 75.42% of Syndax Pharmaceuticals' stock is owned by institutional investors, 1.35% by insiders, and 23.23% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Kynam Capital Management, LP, and Goldman Sachs Group Inc. The largest individual shareholder is Luke Evnin.